Stocks Up as Bullar...
Health Care: Drugs
InterMune Inc. (ITMN: NASDAQ)
$10.00 -0.14 | -1.38%
05/21/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 26.17M | 25.63M | 259.29M | 48.70M |
| Cost of Sales | 5.90M | 5.80M | 6.34M | 7.00M |
| Gross Operating Profit | 20.27M | 19.83M | 252.95M | 41.70M |
| Selling, General, and Administrative Expenses | 105.30M | 90.19M | 55.50M | 37.46M |
| Research & Development | 106.57M | 74.97M | 67.47M | 89.14M |
| Operating Income before D & A (EBITDA) | -191.59M | -145.33M | 129.98M | -84.90M |
| Depreciation & Amortization | 3.01M | 2.91M | 6.43M | 8.63M |
| Interest Income | 586.00K | 556.00K | 571.00K | 1.73M |
| Other Income - Net | -373.00K | -658.00K | 1.60M | -4.62M |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | -30.50M |
| Total Income Before Interest Expenses (EBIT) | -194.40M | -148.34M | 124.42M | -112.36M |
| Interest Expense | 8.93M | 6.41M | 8.40M | 10.13M |
| Pre-Tax Income | -203.32M | -154.75M | 116.02M | -122.49M |
| Income Taxes | -18.63M | 22.00K | 76.00K | 2.15M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -184.69M | -154.77M | 122.37M | -116.02M |
| Net Income From Discontinued Operations | 34.61M | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -150.08M | -154.77M | 122.37M | -116.02M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -150.08M | -154.77M | 122.37M | -116.02M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-184.69M | -154.77M | 123.67M | -100.07M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -184.69M | -154.77M | 122.37M | -116.02M |
| Basic EPS from Continuing Ops. | -2.83 | -2.58 | 2.26 | -2.62 |
| Basic EPS from Discontinued Ops. | 0.53 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -2.30 | -2.58 | 2.26 | -2.62 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -2.30 | -2.58 | 2.26 | -2.62 |
| Basic Normalized Net Income/Share | -2.83 | -2.58 | 2.28 | -2.26 |
| EPS fr Continuing Ops. | -2.83 | -2.58 | 2.13 | -2.62 |
| EPS fr Discontinued Ops | 0.53 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -2.30 | -2.58 | 2.13 | -2.62 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -2.30 | -2.58 | 2.13 | -2.62 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-2.83 | -2.58 | 2.15 | -2.26 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with ITMN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserChopped Liver
- ContributorHot Biotech Stocks Traded b...
- ContributorMost-Searched Stocks for th...
- Userskyisfalling
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Contributor5 Biotech Stocks for 2012
- Contributor3 Health Care Stocks That C...
Latest ITMN Headlines from TheStreet
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- SAC's InterMune Trade Probe May Reveal Corrupted FDA Drug Review 12.10.12 | 02:12 pm
- 7 Stocks Under $10 Making Large Upside Moves 11.23.12 | 12:11 pm
- 4 Health Care Stocks Under $10 Spiking Higher 10.17.12 | 02:10 pm
- Market Preview: A Rally on Fumes 10.02.12 | 05:10 pm
- InterMune's CEO Discusses France's Economic Committee's (CEPS) Authorization Of Reimbursement Of Esbriet Conference (Transcript) 09.11.12 | 06:09 pm
- Analysts' Actions: HD SBUX MUR WAG CVS 08.15.12 | 09:08 am
- InterMune's CEO Discusses Q2 2012 Earnings - Earnings Call Transcript 07.23.12 | 02:07 pm
- Verizon, InterMune: Market Movers 07.23.12 | 12:07 pm
- InterMune: Weak Esbriet Sales But In-Line Pricing 07.23.12 | 08:07 am
Press Releases for ITMN
- InterMune To Release First Quarter Financial Results On April 24 - PR Newswire 04.17.13 | 08:04 am
- Esbriet® (pirfenidone) Receives Positive Final Appraisal Determination From NICE For Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire 03.20.13 | 09:03 pm
- Sean P. Nolan Joins InterMune As Executive Vice President And Chief Business Officer - PR Newswire 02.14.13 | 04:02 pm
- InterMune To Release Fourth Quarter Financial Results On February 21 - PR Newswire 02.11.13 | 08:02 am
- InterMune Announces Pricing Of Concurrent Public Offerings Of $105,000,000 Principal Amount Of Convertible Senior Notes And 13,500,000 Shares Of Common Stock - PR Newswire 01.16.13 | 01:01 am
- InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And Convertible Debt - PR Newswire 01.14.13 | 04:01 pm
- InterMune Reports Preliminary Fourth Quarter 2012 Esbriet® (pirfenidone) Revenue And Other Recent Business Highlights - PR Newswire 01.03.13 | 04:01 pm
- InterMune To Present At J. P. Morgan Healthcare Conference - PR Newswire 01.02.13 | 08:01 am
- InterMune To Release Third Quarter Financial Results On November 7 - PR Newswire 10.31.12 | 08:10 am
- Health Canada Approves Esbriet® As First Treatment For Fatal Lung Disease - PR Newswire 10.02.12 | 04:10 pm
Partner Headlines for ITMN
- Healthcare: Big pharma, big data - Financial Times 04.04.13 | 05:04 pm
- SAC signals further action after $614m deal - Financial Times 03.18.13 | 09:03 pm
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- US authorities widen SAC Capital probe - Financial Times 02.13.13 | 10:02 pm
- 3 High Beta Liquid Small-Cap Biotechnology Stocks That Are Breaking Out - Seeking Alpha 09.17.12 | 09:09 am
- French Reimbursement for Esbriet - Analyst Blog - NASDAQ 09.13.12 | 09:09 pm
- Positive RECAP for ITMN's Esbriet - Analyst Blog - NASDAQ 09.04.12 | 07:09 pm
- InterMune Reports New Analyses from the RECAP Study of Esbriet at ERS - Benzinga 09.03.12 | 11:09 am
- InterMune Earnings Call NUGGETS: Patient Growth, Esbriet on the Path to Success - Wall St. Cheat Sheet 07.25.12 | 01:07 pm
- RadioShack SLIDES to Sell and 4 Anayst-Downgraded Shares - Wall St. Cheat Sheet 07.24.12 | 04:07 am
